Ozempic Maker Novo Nordisk Sinks On Disappointing Earnings Amid Booming Demand For Weight Loss And Diabetes Drugs

Novo Nordisk’s growth has slowed in recent weeks as the company struggles to produce enough semaglutide to meet stellar demand for Wegovy and Ozempic.